Diseases pathophysiology

Rosse WF et al New Views of Sickle Cell Disease Pathophysiology and Treatment. The American Society of Hematology. www.asheducationbook.org... 

Kish, S.J. Shannak, K. and Homykiewicz, O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson s disease. Pathophysiologic and clinical implications. N Engl J Med 318 876-880, 1988. 

Couriel D, Caldera H, Champlin R, Komanduri K. Acute graft-versus-host disease Pathophysiology, clinical manifestations, and management. Cancer 2004 101 1936-1946. 

Ryan JC, Sleisenger MH Effects of systemic and extraintestinal diseases on the gut in Sleisenger MH, Fordtran JS (eds) Gastrointestinal Disease Pathophysiology/Diagnosis/ Management. Philadelphia, Saunders, 1993, pp 193-224. 

Bazan, N. G. and Allan, G. Platelet-activating factor and other bioactive lipids. In M. D. Ginsberg and J. Bogousslavasky (eds), Cerebrovascular Disease, Pathophysiology, Diagnosis and Management. Malden, MA Blackwell Science, 1998, pp. 532-555. 

Lashuel, H. A., Petre, B. M., Wall, J., Simon, M., Nowak, R. J., Walz, T., and Lansbury, P. T., Jr. (2002). Alpha-synuclein, especially the Parkinson s disease-associated mutants, forms pore-like annular and tubular protofibrils./. Mol. Biol. 322,1089-1102. LeVine, H. (1993). Thioflavine T interaction with synthetic Alzheimer s disease beta-amyloid peptides Detection of amyloid aggregation in solution. Protein Sci. 2, 404—410. Lin, H., Bhatia, R., and Lai, R. (2001). Amyloid beta protein forms ion channels Implications for Alzheimer s disease pathophysiology. FASEB J. 15, 2433-2444. Lorenzo, A., and Yankner, B. A. (1994). Beta-amyloid neurotoxicity requires fibril formation and is inhibited by Congo red. Proc. Natl. Acad. Sci. USA 91, 12243-12247. Luhrs, T., Ritter, C., Adrian, M., Riek-Loher, D., Bohrmann, B., Dobeli, H., Schubert, D., and Riek, R. (2005). 3D structure of Alzheimer s amyl o id-( be la) (1—12) fibrils. Proc. Natl. Acad. Sci. USA 102, 17342-17347. 

Giorgio, S., Alessia, L., LUcilla, P., Daniele, T., and Francesso, A. (2006). Treatment of Alzheimer s disease From pharmacology to a better understanding of disease pathophysiology. Mech. Ageing Dev. 127,148-157. 

Semenza GL (2001) Hypoxia-inducible factor 1 oxygen homeostasis and disease pathophysiology. Trends Mol Med 7(8) 345-350... 

Kannan, K., Ortmann, R. A. and Kimpel, D. (2005) Animal models of rheumatoid arthritis and their relevance to human disease. Pathophysiology 12, 167-181. 

S. L. Friedman, G. H. Millward-Sadler, and M. J. P. Arthur, Liver fibrosis and cMhosis, Wright s Liver and Biliary Disease. Pathophysiology, Diagnosis and Management, 3rd ed. (G. H. Millward-Sadler, R. Wright, M. J. P. Arthur, eds.), W. B. Saunders Company Ltd., London Philadelphia Toronto Sydney Tokyo, 1992,... 

Tyagi SC. 1999. Homocysteine and heart disease Pathophysiology of extracellular matrix. Clin Exp Hypertens 21 181-198. 

Busto R. and Ginsberg M. D. (1998) The influence of altered brain temperature in cerebral ischemia. In Cerebrovascular Disease Pathophysiology, Diagnosis and Management (Ginsberg M. D. and Bogousslavsky, J., eds.), Blackwell Science, Malden, pp. 287-307. 

What is evident immediately on attempting to develop a therapy for any particular LSD is the scant (and for many LSDs, virtually absent) information on disease pathophysiology. Beyond recognition of the enzyme deficiency responsible for the disease and the biochemistry of the accumulating substrate, much of the literature is in the form of case reports on individuals or small patient sets, often with minimal characterization of disease pathology. The paradox is that a more complete body of literature only develops after an effective treatment becomes available (e.g., Gaucher and Fabry diseases). Considerable initial research is therefore needed by any company seeking a successful therapeutic for a specific LSD. 

Colosimo C, De Michele M. Motor fluctuations in Parkinson s disease pathophysiology and treatment. Eur J Neurol 1999 6(1) 1-21. 

Hofmann, AJ. Cholestatic liver disease Pathophysiology and therapeutic options. Liver 2002 22 (Suppl. 2) 14—19... 

---